Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of human and murine cytotoxic T lymphocytes, and in the growth and differentiation of tumor cells. Bryostatin 1 has immunomodulating and antitumor properties as demonstrated by preclinical and clinical studies. Here we report that bryostatin 1 increases the susceptibility to lymphokine activated killers and modifies the pattern of beta 1 integrin expression of human tumor cells. On the basis of these results the use of bryostatin 1 in combination with immunostimulating cytokines such as interleukin-2 in the treatment of human cancer is suggested.
Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the b1 integrin profile of cultured human tumor cells / P., Correale; M., Caraglia; Fabbrocini, Antonietta; R., Guarrasi; Pepe, Stefano; V., Patella; Marone, Gianni; A., Pinto; Bianco, ANGELO RAFFAELE; P. T. a. g. l. i. a. f. e. r. r., I.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 6:2(1995), pp. 285-290.
Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the b1 integrin profile of cultured human tumor cells.
FABBROCINI, ANTONIETTA;PEPE, STEFANO;MARONE, GIANNI;BIANCO, ANGELO RAFFAELE;
1995
Abstract
Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of human and murine cytotoxic T lymphocytes, and in the growth and differentiation of tumor cells. Bryostatin 1 has immunomodulating and antitumor properties as demonstrated by preclinical and clinical studies. Here we report that bryostatin 1 increases the susceptibility to lymphokine activated killers and modifies the pattern of beta 1 integrin expression of human tumor cells. On the basis of these results the use of bryostatin 1 in combination with immunostimulating cytokines such as interleukin-2 in the treatment of human cancer is suggested.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
